therapeutic action: antifungal activity against Candida albicans

Efficacy of Rezafungin on Candida albicans Endophthalmitis in a Rabbit Model

mycolabadmin

Researchers tested a new antifungal drug called rezafungin against a serious eye infection caused by Candida fungus in rabbits. Rezafungin performed much better than two other commonly used antifungal drugs, completely eliminating the fungus from the eye while preventing infection-related damage. The drug’s ability to be given weekly instead of daily makes it more practical for treating patients with severe fungal eye infections.

Read More »

Evaluation of Antifungal Activity Against Candida albicans Isolates From HIV-Positive Patients with Oral Candidiasis in a Major Referral Hospital, West Java, Indonesia

mycolabadmin

Researchers in West Java, Indonesia studied fungal infections in the mouths of HIV-positive patients to understand which antifungals work best. They found that a common fungal species called Candida albicans was present in all patients tested, though some resistant strains were discovered. The study showed that certain antifungal medications like voriconazole worked better than others, highlighting the importance of testing which specific medications will be effective for each patient rather than guessing.

Read More »

Rediscovery of viomellein as an antibacterial compound and identification of its biosynthetic gene cluster in dermatophytes

mycolabadmin

Researchers discovered that dermatophytes, fungi that cause common skin infections like athlete’s foot, produce a red pigment called viomellein that kills bacteria. By studying the genes responsible for making this compound, scientists found that most dermatophytes produce it, which may help explain how these fungi establish infections on skin despite the presence of protective bacteria. This discovery opens new possibilities for understanding skin infections and potentially developing new treatments.

Read More »
Scroll to Top